Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL

被引:424
作者
Griffith, TS
Wiley, SR
Kubin, MZ
Sedger, LM
Maliszewski, CR
Fanger, NA
机构
[1] Immunex Corp, Dept Discovery Recovery, Seattle, WA 98101 USA
[2] Immunex Corp, Dept Bioinformat, Seattle, WA 98101 USA
[3] Immunex Corp, Dept Immunobiol, Seattle, WA 98101 USA
关键词
TRAIL; apoptosis; tumor; monocyte; human;
D O I
10.1084/jem.189.8.1343
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
TRAIL (tumor necrosis factor [TNF]-related apoptosis-inducing Ligand) is a molecule that displays potent antitumor activity against selected targets. The results presented here demonstrate that human monocytes rapidly express TRAIL, but not Fas ligand or TNF, after activation with interferon (IFN)-gamma or -alpha and acquire the ability to kill tumor cells. Monocyte-mediated tumor cell apoptosis was TRAIL specific, as it could be inhibited with soluble TRAIL receptor. Moreover, IFN stimulation caused a concomitant loss of TRAIL receptor 2 expression, which coincides with monocyte acquisition of resistance to TRAIL-mediated apoptosis. These results define a novel mechanism of monocyte-induced cell cytotoxicity that requires TRAIL, and suggest that TRAIL is a key effector molecule in antitumor activity in vivo.
引用
收藏
页码:1343 / 1353
页数:11
相关论文
共 58 条
[1]   MOLECULAR-INTERACTIONS IN MACROPHAGE ACTIVATION [J].
ADAMS, DO .
IMMUNOLOGY TODAY, 1989, 10 (02) :33-35
[2]   THE CELL BIOLOGY OF MACROPHAGE ACTIVATION [J].
ADAMS, DO ;
HAMILTON, TA .
ANNUAL REVIEW OF IMMUNOLOGY, 1984, 2 :283-318
[3]   FAS LIGAND MEDIATES ACTIVATION-INDUCED CELL-DEATH IN HUMAN T-LYMPHOCYTES [J].
ALDERSON, MR ;
TOUGH, TW ;
DAVISSMITH, T ;
BRADDY, S ;
FALK, B ;
SCHOOLEY, KA ;
GOODWIN, RG ;
SMITH, CA ;
RAMSDELL, F ;
LYNCH, DH .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (01) :71-77
[4]   Macrophage-dependent apoptosis of CD4(+) T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor [J].
Badley, AD ;
Dockrell, D ;
Simpson, M ;
Schut, R ;
Lynch, DH ;
Leibson, P ;
Paya, CV .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (01) :55-64
[5]   Cellular responses to interferon-gamma [J].
Boehm, U ;
Klamp, T ;
Groot, M ;
Howard, JC .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :749-795
[6]   Priming of human CD4(+) antigen-specific T cells to undergo apoptosis by HIV-infected monocytes - A two-step mechanism involving the gp120 molecule [J].
Cottrez, F ;
Manca, F ;
Dalgleish, AG ;
ArenzanaSeisdedos, F ;
Capron, A ;
Groux, H .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (02) :257-266
[7]   The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain [J].
Degli-Esposti, MA ;
Dougall, WC ;
Smolak, PJ ;
Waugh, JY ;
Smith, CA ;
Goodwin, RG .
IMMUNITY, 1997, 7 (06) :813-820
[8]   Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family [J].
DegliEsposti, MA ;
Smolak, PJ ;
Walczak, H ;
Waugh, J ;
Huang, CP ;
DuBose, RF ;
Goodwin, RG ;
Smith, CA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (07) :1165-1170
[9]  
DING AH, 1988, J IMMUNOL, V141, P2407
[10]   The expression of Fas ligand by macrophages and its upregulation by human immunodeficiency virus infection [J].
Dockrell, DH ;
Badley, AD ;
Villacian, JS ;
Heppelmann, CJ ;
Algeciras, A ;
Ziesmer, S ;
Yagita, H ;
Lynch, DH ;
Roche, PC ;
Leibson, PJ ;
Paya, CV .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (11) :2394-2405